Clinical trials
catalyst calendar across sponsors →Studies where IPSC is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional · 1 observational
Held by 10 tracked-famous managers (Balyasny Asset Management L.P., Point72 Asset Management, L.P., MILLENNIUM MANAGEMENT LLC, TWO SIGMA INVESTMENTS, LP, RENAISSANCE TECHNOLOGIES LLC, +5 more) · FINRA short interest 40.7 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 4 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy ProductNCT05768269observationalNumber of Participants With any Adverse Events of Special Interest (AESI) | — | Recruiting | Other: No Intervention | Hematological Malignancy, Solid Tumor Malignancy | 375 | Mar 2040 | ≤ 4,973 d | 2025-06-25 |
| A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune DiseasesNCT06255028Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Severity of TEAEsNon-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Biological: CNTY-101, IL-2 · Drug: Lymphodepleting Chemotherapy | Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis | 6 | Aug 2028 | ≤ 743 d | 2026-01-08 |
| A Study of CNTY-101 in Participants With CD19-Positive B-Cell MalignanciesNCT05336409Maximum Tolerated Dose (MTD) as Determined by the Percentage of Participants With Dose Limiting Toxicities (DLTs) and DLTs Based on SeverityNon-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Strategic decision | Biological: CNTY-101, IL-2 · Drug: Lymphodepleting Chemotherapy | R/R CD19-Positive B-Cell Malignancies, Indolent Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma | 28 | 2025-07-01actual | — | 2025-12-18 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19